BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18158775)

  • 1. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
    Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
    Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
    J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
    Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
    J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
    Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
    J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine.
    Doberauer C; Ohl S
    Acta Derm Venereol; 1989; 69(6):538-40. PubMed ID: 2481928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
    Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
    Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
    [No Abstract]   [Full Text] [Related]  

  • 15. Disappearance of seborrheic keratoses following treatment with methotrexate.
    Seyfer SJ; Duvic M
    Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
    Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
    Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sézary syndrome in an 11-year-old girl.
    Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
    J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.